These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 22338574)

  • 1. Platelets in atherothrombosis--diagnostic and prognostic value of platelet activation in patients with atherosclerotic diseases.
    Bigalke B; Schuster A; Sopova K; Wurster T; Stellos K
    Curr Vasc Pharmacol; 2012 Sep; 10(5):589-96. PubMed ID: 22338574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease-Activated Receptor 1 Inhibitors: Novel Antiplatelet Drugs in Prevention of Atherothrombosis.
    Al-Khafaji K; Mutyala M; Al-Khafaji N; Harper Y; Ismail I; Hakim H; Arora RR
    Am J Ther; 2017; 24(6):e730-e736. PubMed ID: 26398717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant GPVI-Fc added to single or dual antiplatelet therapy in vitro prevents plaque-induced platelet thrombus formation.
    Mojica Muñoz AK; Jamasbi J; Uhland K; Degen H; Münch G; Ungerer M; Brandl R; Megens R; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2017 Aug; 117(8):1651-1659. PubMed ID: 28569920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The basis of platelets: platelets and atherothrombosis: an understanding of the lack of efficacy of aspirin in peripheral arterial disease (PAD) and diabetic patients].
    Drouet L; Bal dit Sollier C; Henry P
    Drugs; 2010 Nov; 70 Suppl 1():9-14. PubMed ID: 20977287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplified inhibition of atherosclerotic plaque-induced platelet activation by glenzocimab with dual antiplatelet therapy.
    Alenazy FO; Harbi MH; Kavanagh DP; Price J; Brady P; Hargreaves O; Harrison P; Slater A; Tiwari A; Nicolson PLR; Connolly DL; Kirchhof P; Kalia N; Jandrot-Perrus M; Mangin PH; Watson SP; Thomas MR
    J Thromb Haemost; 2023 Nov; 21(11):3236-3251. PubMed ID: 37541591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycoprotein VI - novel target in antiplatelet medication.
    Borst O; Gawaz M
    Pharmacol Ther; 2021 Jan; 217():107630. PubMed ID: 32681846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiplatelet drugs in cardiological practice: established strategies and new developments.
    Krötz F; Sohn HY; Klauss V
    Vasc Health Risk Manag; 2008; 4(3):637-45. PubMed ID: 18827913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
    Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
    Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of receptor shedding-platelet GPVI as an emerging diagnostic and therapeutic tool.
    Chatterjee M; Gawaz M
    Platelets; 2017 Jun; 28(4):362-371. PubMed ID: 27753514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of antiplatelet drugs in the prevention of cardiovascular events.
    Tendera M; Wojakowski W
    Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorapaxar: A Protease-Activated Receptor Antagonist for the Prevention of Thrombotic Events.
    Lam S; Tran T
    Cardiol Rev; 2015; 23(5):261-7. PubMed ID: 25923910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is a variability of platelet inhibitory effect of anti-platelet agents important for predicting new lesion in atherothrombotic stroke?
    Jung JM; Park JW; Kim SU; Kwon DY; Park MH
    Int J Stroke; 2018 Aug; 13(6):NP14-NP15. PubMed ID: 29676226
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet and soluble glycoprotein VI - novel applications in diagnosis and therapy.
    Bigalke B; Elvers M; Schönberger T; Gawaz M
    Curr Drug Targets; 2011 Nov; 12(12):1821-30. PubMed ID: 21718237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50).
    Bonaca MP; Gutierrez JA; Creager MA; Scirica BM; Olin J; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2016 Mar; 133(10):997-1005. PubMed ID: 26826179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease.
    Slater A; Khattak S; Thomas MR
    Eur Heart J Cardiovasc Pharmacother; 2024 Aug; 10(5):465-473. PubMed ID: 38453424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
    Moon JY; Franchi F; Rollini F; Angiolillo DJ
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
    Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
    Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
    Wadowski PP; Eichelberger B; Kopp CW; Pultar J; Seidinger D; Koppensteiner R; Lang IM; Panzer S; Gremmel T
    J Cardiovasc Transl Res; 2017 Aug; 10(4):359-367. PubMed ID: 28425039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond antiplatelets: The role of glycoprotein VI in ischemic stroke.
    Induruwa I; Jung SM; Warburton EA
    Int J Stroke; 2016 Aug; 11(6):618-25. PubMed ID: 27312676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
    Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
    J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.